Recombinant canine stromelysin 3 inhibits drug induced apoptosis in vitro

B V SUNIL KUMAR; MEENA KATARIA; REDDI V V S N MURTHY; MEETA SAXENA; BHASKAR SHARMA

doi:10.56093/ijans.v85i1.46132

Authors

B V SUNIL KUMAR Assistant Biochemist, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab 141 004 India
MEENA KATARIA Principal Scientist, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab 141 004 India
REDDI V V S N MURTHY Ph.D Student, School of Animal Biotechnology, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab
MEETA SAXENA Technical Officer, Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab 141 004 India
BHASKAR SHARMA National Professor Sharma, Division of Biochemistry, Indian Veterinary Research Institute, Izatnagar, Bareilly, Uttar Pradesh

https://doi.org/10.56093/ijans.v85i1.46132

Keywords:

Apoptosis, FACS, Matrix metalloproteinases, Stromelysin 3, Vinblastine

Abstract

Matrix metalloproteinases (MMPs) are zinc metalloproteases having a pivotal role in extracellular matrix degradation, tumor growth, apoptosis, angiogenesis, invasion, and development of metastases. Stromelysin 3 (ST3) increased tumor take by suppressing cell apoptosis. Our present goal was to set up an in vitro model in which we could study this new function of ST3. For this purpose, we analysed effect of vinblastine, an anti-cancer drug, on ST3 treated MDCK (Madin-Darby canine kidney) cells. We found a marked decrease in the percentage of vinblastine induced MDCK cell death when the cells were pre-treated with recombinant ST3 as assessed by FACS analysis. Our data confirmed and extended the anti-apoptotic function of ST3 in-vitro.

Downloads

Download data is not yet available.

References

Anderson I C, Sugarbaker D J, Ganju R K, Tsarwhas D G, Richards W G, Sunday M, Kobzik L and Shipp M A. 1995. Stromelysin- 3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Research 55: 4120 –26.

Baserga R. 2000. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 19: 5574–81. DOI: https://doi.org/10.1038/sj.onc.1203854

Boulay A, Masson R, Chenard M P, El Fahime M, Cassard L, Bellocq J P, Sautes-Fridman C, Basset P and Rio M C. 2001. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Research 61: 2189–93.

Brinckerhoff C E and Matrisian L M. 2002. Matrix metalloproteinases: a tail of a frog that became a prince. Nature Reviews Molecular Cell Biology 3: 207–14. DOI: https://doi.org/10.1038/nrm763

Damjanovski S, Ishizuya-Oka A and Shi Y B. 1999. Spatial and temporal regulation of collagenases-3, –4, and stromelysin -3 implicates distinct functions in apoptosis and tissue remodeling during frog metamorphosis. Cell Research 9: 91–105. DOI: https://doi.org/10.1038/sj.cr.7290009

Egeblad M and Werb Z. 2002. New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2: 161–74. DOI: https://doi.org/10.1038/nrc745

Ishizuya-Oka A, Li Q, Amano T, Damjanovski S, Ueda S and Shi Y B. 2000. Requirement for matrix metalloproteinase stromelysin-3 in cell migration and apoptosis during tissue remodeling in Xenopus laevis. Journal of Cell Biology 150: 1177–88. DOI: https://doi.org/10.1083/jcb.150.5.1177

Lockshin R A and Zakeri Z. 2004. Caspase-independent cell death. Oncogene 23: 2766–73. DOI: https://doi.org/10.1038/sj.onc.1207514

Noel A, Gutiérrez-Fernández A, Sounni NE, Behrendt N, Maquoi E, Lund I K, Cal S, Hoyer-Hansen G and López-Otín C. 2012. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Frontiers in Pharmacology 3: 1–9. DOI: https://doi.org/10.3389/fphar.2012.00140

Rouyer N, Wolf C, Chenard M P, Rio M C, Chambon P, Bellocq J P and Basset P. 1994. Stromelysin-3 gene expression in human cancer: an overview. Metastasis 14: 269 –75

Snedecor G W and Cochran W G. 1994. One way classification: analysis of variance. Snedecor GW, Cochran WG, (Eds). Statistical Methods. Affiliated East-West Press, India 217–36.

Sternlicht M D, Werb Z. 2001. How matrix metalloproteinases regulate cell behaviour. Annual Review of Cell and Developmental Biology 17: 463–16. DOI: https://doi.org/10.1146/annurev.cellbio.17.1.463

Strand S, Vollmer P and Van de Abeelen L. 2004. Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumor cells. Oncogene 23: 3732–36. DOI: https://doi.org/10.1038/sj.onc.1207387

Sunil Kumar B V, Aswani Kumar K, Padmanath K, Sharma B and Kataria M. 2013. Heterologous expression and functional characterization of matrix metalloproteinase-11 from canine mammary tumor. Animal Biotechnology 24(1): 31–43. DOI: https://doi.org/10.1080/10495398.2012.739978

Vu T H and Werb Z. 2000. Matrix metalloproteinases: effectors of development and normal physiology. Genes and Development. 14: 2123–33. DOI: https://doi.org/10.1101/gad.815400

Wu E, Mari B P, Wang F, Anderson I C, Sunday M E and Shipp M A. 2001. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. Journal of Cell Biochemistry 82: 549–55. DOI: https://doi.org/10.1002/jcb.1181